Other languages RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
4.63 ^USD	+0.87%		+9.07%	-81.37%

May. 14	Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform	MT
May. 10	Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US Equity Markets Close Higher Thursday as Jobless Claims Climb	May. 09
Sector Update: Health Care Stocks Higher Late Afternoon	May. 09
Sector Update: Health Care	May. 09
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials	May. 09
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	Apr. 09
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
RAPT Therapeutics Shares Decline Following UBS Downgrade	Feb. 22
Sector Update: Health Care Stocks Lower Late Afternoon	Feb. 20
Top Midday Decliners	Feb. 20
FDA puts on hold two Rapt Therapeutics mid-stage drug trials	Feb. 20
RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon in Atopic Dermatitis and its Phase 2a Trial in Asthma	Feb. 20
RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations	Feb. 13
RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon to Treat Atopic Dermatitis in Allergy	Nov. 27
RAPT Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
RAPT Therapeutics Shares Jump After Positive Data From Phase 2 Trial of FLX475 Plus Pembrolizumab in Cancer Patients	Nov. 03
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC	Nov. 03
RAPT Therapeutics Files for Shelf Offering	23-08-11
RAPT Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Other languages

Filters